The announcement follows just days after the US Centres for Disease Control confirmed its first death from Avian Influenza.

IO Biotech has finished enrolling subjects in a Phase II trial of IO102-IO103 in conjunction with MSD's KEYTRUDA (pembrolizumab).

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is enacting lay-offs, cutting 73% of jobs.

Alentis Therapeutics has reported positive topline outcomes from two clinical trials of lixudebart (ALE.F02) for reversing organ fibrosis.

Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM).